Compare FRD & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRD | ARMP |
|---|---|---|
| Founded | 1965 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.3M | 156.4M |
| IPO Year | 1995 | 1996 |
| Metric | FRD | ARMP |
|---|---|---|
| Price | $35.37 | $4.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 73.2K | ★ 157.0K |
| Earning Date | 06-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $121,157,278.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.33 | ★ N/A |
| Revenue Growth | ★ 55.82 | N/A |
| 52 Week Low | $15.10 | $2.36 |
| 52 Week High | $39.07 | $14.98 |
| Indicator | FRD | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 53.75 | 47.69 |
| Support Level | $30.68 | $4.81 |
| Resistance Level | $37.08 | $5.50 |
| Average True Range (ATR) | 2.31 | 0.54 |
| MACD | -0.32 | 0.15 |
| Stochastic Oscillator | 44.34 | 79.70 |
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.